MADE in America Act
- Last Action
- 12/17/2024
Actions
- 2024-12-17Referred to the Subcommittee on Health.
- 2023-04-19Referred to the House Committee on Ways and Means.
- 2023-04-19Introduced in House
- 2023-04-19Introduced in House
CRS Summary
As of 2023-04-19 (00)
Manufacturing API, Drugs, and Excipients in America Act or the MADE in America Act
This bill establishes a tax credit for certain manufacturers of pharmaceuticals or medical products.
Specifically, the bill establishes a tax credit for manufacturers of pharmaceuticals, active pharmaceutical ingredients, excipients (i.e., inactive ingredients), medical diagnostic devices, or personal protective equipment, if they are located in a designated distressed zone. The tax credit is equal to 25% of the manufacturer's production expenditures; the credit increases to 30% of expenditures if a substantial portion of the manufacturer's employees reside in a distressed zone.
The bill defines distressed zone as an area that has been designated as a qualified opportunity zone by the Internal Revenue Service (i.e., an economically distressed community in which certain new investments may be eligible for preferential tax treatment) and that has a poverty rate of over 30%.
Cosponsors (13)
- Darren Soto (D-FL)
- Carol Miller (R-WV)
- Matt Cartwright (D-PA)
- Richard Hudson (R-NC)
- Gus Bilirakis (R-FL)
- H. Griffith (R-VA)
- Troy Balderson (R-OH)
- Jefferson Van Drew (R-NJ)
- Eric Crawford (R-AR)
- Diana Harshbarger (R-TN)
- Nicholas Langworthy (R-NY)
- Ronny Jackson (R-TX)
- John Rutherford (R-FL)
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.